Drug intelligence / Profile preview

D5884

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

D5884 is an investigational compound that was studied in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics following single and multiple oral doses in healthy male Japanese and Caucasian subjects. The study was conducted by AstraZeneca. The available information does not specify the mechanism of action, therapeutic class, or primary indication for D5884. It appears to be a small molecule drug candidate evaluated for basic science purposes in early-stage clinical research[1][4].

Beyond the preview

Go deeper on D5884.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D5884.

Explore the full profile